Boehringer Ingelheim at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Boehringer Ingelheim brings 8 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 221, Suite 24, Suite 25. Its program centres on obesity and MASLD as linked metabolic diseases, and on measuring eating behavior from the patient's point of view. It covers validation of an eating behavior patient-reported measure in Europe and Japan and a long-acting NMUR2-GIPR dual agonist that adds weight loss through complementary satiety pathways.

OrganizationObesityWeek 2026 Attendance
Boehringer Ingelheim
Ingelheim, Germany
◆Gold Sponsor
Large pharmaGold Sponsor
Family-owned pharmaceutical company developing treatments for obesity and MASH, including the glucagon and GLP-1 dual agonist survodutide.
Booth
Exhibiting at Booth 221, Suite 24, Suite 25
Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm
Talk
Sat Nov 14
3:30pm–3:45pm
A Long-Acting NMUR2–GIPR Dual Agonist Provides Additive Body‑Weight Loss by Modulation of Complementary Satiety Pathways
Woodrow Wilson, Ballroom Level
Metabolism and Integrative Physiology · Pharmacology · Pediatrics · Chronic Disease
Talk
Sun Nov 15
11:45am–1:15pm
Bridging Obesity and MASLD Through Metabolic Dysfunction
Links obesity, visceral and liver fat, and MASLD, making the case for waist measures and early liver checks, with patients describing their own experience.
Riverview Ballroom A
with knownwell
Metabolism and integrative physiologyChronic disease and obesity complications
Poster
Sun Nov 15
2:30pm–3:30pm
Talk
Sun Nov 15
6:30pm–8:30pm
Clinical Case Files: Following the Metabolic Clues in Obesity and MASLD
Case-based problem-solving on spotting MASLD risk early and coordinating liver and metabolic care for patients with obesity.
Riverview Ballroom A
with University of Alabama at Birmingham, Weill Cornell Medicine
Metabolism and integrative physiologyClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complications
Talk
Mon Nov 16
11:45am–12:45pm
Glucagon’s Role in Metabolic Regulation and Why It Matters
Covers how glucagon and the liver regulate glucose and fat metabolism and why this matters in obesity and related heart, kidney and metabolic diseases.
Riverview Ballroom B
with Wake Forest University, UT Southwestern Medical Center, Weill Cornell Medicine +2 more
Metabolism and integrative physiologyChronic disease and obesity complications

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Boehringer Ingelheim

Tell us what you sell and we’ll find the people at Boehringer Ingelheim most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction